DATE: September 12, 2019
TIME: 8:00am PDT
In the upcoming era of personalized medicine, there is a growing need for the development of rapid, sensitive, precise and accurate analysis of tissues in their native environment. By preserving the samples in their original state, without the need of sample preparation, scientists and clinicians can better decipher the underlying biological mechanisms required in clinical applications. For example, the improvement of cancer treatment and prognosis highly relays on the development of novel technologies allowing for rapid molecular diagnosis in an intraoperative context of cancer surgery.
The development and use of ambient ionization MS (AIMS) techniques has become widespread since they require minimal sample preparation for analysis, contrary to traditional vacuum based MS approaches. In the first instance AIMS were used for tissue profiling and biomarker discovery and in the second, for imaging in combination with histology for morphology-based tissue analysis. The next step is to bring these MS technologies even closer to the patients for in vivo and real-time sampling. This has been achieved by the development of several in vivo probes. Amongst them is the SpiderMass system which has been developed at the PRISM Laboratory (Lille) and successfully applied in several clinical projects. The most recent applications enabled tumor typing and grading of dog ex vivo sarcoma biopsies in the lab and in vivo tissues during surgery in a veterinary surgical theatre.
- How MS development has advanced in clinical labs and hospitals
- How the molecular information obtained by MS can be related to health and disease
- How the SpiderMass developed in PRISM can help clinicians in their daily routine
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.